TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04019301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin Qigong, Community-based
Description: The Community-based Qigong group, will attend one 75 minute long Qigong class per week for 12 weeks. Additionally, participants practice Qigong at home for 20 minutes a day, 3 days a week. Printed materials will be provided to guide home practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin Qigong, Internet-based
Description: The Internet-guided Qigong group will be given a computer tablet to access online Qigong classes. All participants assigned to this group will be provided with a tutorial to use the Qigong program by the research coordinator. Participants will be asked to follow a 40 minute long Qigong class twice a week for 12 weeks, and to practice an additional 20 minutes a day, 3 days a week. All sessions will be completed at home.
Study: NCT01033123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSI-201
Description: IV infusion, 5.6 mg/kg
Study: NCT02376062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundled Intervention
Description: The authors have designed continuing medical education curriculum to improve clinical capacity and competency about mental health for Nepali Primary Care Providers. Specifically:~* On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~* Weekly case conferences~* Surveys of clinicians and clinical supervisors in accordance with CME curriculum
Study: NCT01236144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1\&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1\&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
Study: NCT03807934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation via Soterix Medical or Neuroelectrics noninvasive brain stimulation systems
Description: Active (at or below 2mA) versus sham (at or below 0.5mA) stimulation targeting brain regions engaged during verbal and/or spatial perceptual and cognitive processing. Brain stimulation devices are not currently regulated by the United States Food and Drug Administration. Local IRB has determined the devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stimulation via Soterix Medical or Neuroelectrics noninvasive brain stimulation systems
Description: Active (at or below 2mA) versus sham (at or below 0.5mA) stimulation targeting brain regions engaged during verbal and/or spatial perceptual and cognitive processing. Brain stimulation devices are not currently regulated by the United States Food and Drug Administration. Local IRB has determined the devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
Study: NCT01234467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
Study: NCT01585142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test formula
Description: Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition
Study: NCT03699761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of the pelvic peritoneum
Description: Closure of the pelvic peritoneum after anastomosis for middle-low rectal caner.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonclosure of the pelvic peritoneum
Description: Nonclosure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
Study: NCT04374175

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sample will be performed

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sample will be performed
Study: NCT01525888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)
Description: stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker
Study: NCT03199456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zip surgical skin closure device
Description: Zip surgical skin closure device manufactured by ZipLine Medical, Inc. is a CE-marked, non-invasive, single use device that is designated to provide closure of the skin layer for lacerations or surgical incisions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care sutures
Description: Standard of Care sutures according to the hospitals current clinical praxis.
Study: NCT03890692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flexible nasoendoscopy
Description: nasopharyngeal endoscopy : After washing nasal cavities with a sterile physiologic solution to remove secretions or scabs, and decongesting them with an oxymetazoline solution in the subjects with turbinate hypertrophy,~* Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\\ septum\\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists
Study: NCT03490188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge Mentoring
Description: Phone Conversations on the importance of complying to discharge instructions delivered before discharge
Study: NCT02074709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain bupivacaine
Description: Intraoperative: TAP block with plain bupivacaine + Acetaminophen 1000 mg IV + Ketorolac 30 mg IV .~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h,prn

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Group intraoperative: Wound infiltration with liposomal bupivacaine (Exparel) + IV acetaminophen 1000 mg IV + Ketorolac 30 mg IV~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn
Study: NCT02301078

Intervention type: PROCEDURE
Intervention: Percutaneous Needle Aponeurotomy
Description: single procedure (day 0)

Intervention type: DRUG
Intervention: Collagenase clostridium histolyticum
Description: Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
Study: NCT01280760

Intervention type: OTHER
Intervention: Device: Neurally Adjusted Ventilatory Assistance
Description: Device: Neurally Adjusted Ventilatory Assistance~In ICU following extubation NIV was performed as follows:~facial mask with PSV/NIV mode to define settings for NAVA ventilation facial use with NAVA/NIV mode
Study: NCT02698319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Copenhagen Triage Algorithm
Description: The Copenhagen Triage Algorithm is a new triage method for faster triage in the ED
Study: NCT04195867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol Xinafoate
Description: Subjects receive a daily inhaled dose of 200 μg (4 inhalations of 50 μg each).
Study: NCT01502267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose IVIG and B cell depleting agents
Description: 1. IVIG(2g/kg two times on day 1, 30)~2. Rituximab(375mg/m2 on day 3)~3. Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)
Study: NCT01603927

Intervention type: DEVICE
Intervention: Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).
Description: Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
Study: NCT01556659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Absence of vitamin K antagonist
Description: Dual anti-platelet therapy
Study: NCT03360721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT01410149

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAV
Description: Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
Study: NCT04066842

Intervention type: OTHER
Intervention: Observation
Description: Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Observation
Description: Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Observation
Description: Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Observation
Description: Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease
Study: NCT01410149

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSV
Description: Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACV
Description: Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
Study: NCT04001582

Intervention type: OTHER
Intervention: Patient Registry
Description: Participants who have volunteered to participate will complete various questionnaires relating to their condition.
Study: NCT01788969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: Agent + training vs Placebo + training

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Agent + training vs Placebo + training
Study: NCT04216953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Adults: 20mg film coated tablet~Paediatrics:~i) powder for oral suspension containing 250mg of cobimetinib~ii) for pediatric patients ≥12 years-old and with a BW ≥60kg : 20mg film coated tablet same as adults

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 20-mL glass vial containing 1200 mg of atezolizumab.
Study: NCT02837250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pos4Health
Description: This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
Study: NCT02596009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breezhaler®
Description: No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Ellipta®
Description: No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Handihaler®
Description: No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
Study: NCT03669627

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: aTIV Primer
Description: MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aTIV Primer
Description: MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: QIV Primer
Description: Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aTIV Booster
Description: MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV Booster
Description: Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: QIV Booster
Description: Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2
Study: NCT00702130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: pravastatin 40mg per os once daily
Study: NCT01018459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 Circumsporozoite Malaria Vaccine
Description: Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10\^9 viral particles (vp)/mL, 10\^10 vp/mL, 5 x 10\^10 vp/mL, and 10\^11 vp/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 Circumsporozoite Malaria Vaccine
Description: Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10\^9 viral particles (vp)/mL, 10\^10 vp/mL, 5 x 10\^10 vp/mL, and 10\^11 vp/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 Circumsporozoite Malaria Vaccine
Description: Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10\^9 viral particles (vp)/mL, 10\^10 vp/mL, 5 x 10\^10 vp/mL, and 10\^11 vp/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 Circumsporozoite Malaria Vaccine
Description: Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10\^9 viral particles (vp)/mL, 10\^10 vp/mL, 5 x 10\^10 vp/mL, and 10\^11 vp/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
Study: NCT00545831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolidine
Description: 2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic Serum
Description: 2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
Study: NCT01650181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients with Steatohepatitis treated with diet, exercise and metformin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Siliphos+ Selenium - Methionine + Alpha Lipoic Acid
Description: Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Siliphos+ Selenium - Methionine + Alpha Lipoic Acid
Description: Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients with fatty liver treated with diet, exercise and metformin
Study: NCT00559962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733
Description: 3 capsules each evening for each 4-week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 capsules each evening for each 4-week period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733
Description: 3 capsules each evening for each 4-week period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733
Description: 3 capsules each evening for each 4-week period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733
Description: 3 capsules each evening for each 4-week period
Study: NCT00717808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranilast
Description: Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
Study: NCT01495793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied.
Study: NCT01327066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 600 mg, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 2000 mg, single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg, single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg, single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Droxidopa or Moxifloxacin
Study: NCT03302221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine paravertebral block
Description: The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine epidural block
Description: A 4-5 ml bolus of 0.25% ropivacaine was administered 1 h after the initiation of TEB.

Intervention type: DRUG
Group type: OTHER
Intervention: 0.5% ropivacaine local anaesthesia
Description: local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
Study: NCT02769182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring and training using the system
Description: subjects and caregivers will be trained on using the system and receive a 'user manual' delineating all procedures and possible applications of the system, as well as operations for daily charging of the sensors and smart phone. They will then be fitted with the sensors. The clinician will set all necessary applications, including setting the cognitive games application and the 'network of users'. Users and care givers will be informed of the personalized recommendations system that will provide the user with daily feedback on activity and weekly recommendations and goals for duration of the study. A helpline will be provided in case technological problems occur or for routine support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Subjects in this group will not receive the system but will encouraged to continue with their daily living routine and provided with recommendations for stretching and strengthening exercises. The control group subjects will be assessed at the same three time points as those in the experimental group. Subjects in both groups will also receive written information about the importance of activity, cognitive enhancing tasks, avoidance of falls and home hazards. In Israel, this information combined with an exercise prescription is considered the 'standard of care' for community-dwelling older adults.
Study: NCT01694927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
Study: NCT02057224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation using Medtronic Symplicity System (mono-electrode)
Description: Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.